“Likely” Merck Consumer-Health Sale Could Bring $8 Billion – Analysts
This article was originally published in The Rose Sheet
Executive Summary
Merck executives shift their position regarding the potential divestiture of non-pharma assets, including the firm’s consumer-health business. J.P. Morgan analysts expect a sale of the consumer unit, and say Merck’s brands, including Claritin and Coppertone, could grow globally with a new owner.
You may also be interested in...
Bayer Buys Merck Consumer Biz, Aiming For Top Of Global OTC Industry
The $14.2 billion deal is “a major milestone on our path toward global leadership” in OTC sales, says Bayer Chairman Marijn Dekkers. The acquisition focuses on expanding international sales of Merck products including the Coppertone sunscreen, Claritin allergy and MiraLax constipation lines.
Sales & Earnings In Brief: Merck evaluates consumer business, Perrigo expects more nasal steroid switches, Pfizer consumer sales flat, Sanofi consumer grows nearly 10%
Merck evaluates consumer business; Perrigo expects more nasal steroid switches; Pfizer consumer segment flat; Sanofi consumer sales grow nearly 10%; Bayer consumer slips; more Sales & Earnings In Brief
Divestiture Possible For Merck’s Animal Health, Consumer Units; Januvia’s Sales Slide
The performance of Merck’s diabetes franchise came under scrutiny by analysts on an earnings call Oct 28, after the company reported sales of its number one drug fell 5% in the third quarter year on year. Top executives came closer than ever to saying they are inclined to divest non-core businesses, including animal health.